Table 1.
Patient characteristics of whole cohort, patients treated with CYP, RTX, and/or BTZ and remaining patients.
| Whole cohort | Patients treated with CYP, RTX, and/or BTZ | Remaining patients | p value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | n | n | ||||||||
| Gender, male/female | 138/62 | 200 | 35/13 | 48 | 103/49 | 153 | ||||
| Age at first diagnosis, mean ± SD | 57.0 | 13.8 | 186 | 55.2 | 12.0 | 48 | 57.7 | 14.4 | 139 | 0.27 |
| INCAT-ODSS at initial diagnosis, mean ± SD | 2.3 | 1.9 | 169 | 3.1 | 2.5 | 48 | 2.0 | 1.6 | 121 | <0.01 |
| MRC sum score at initial diagnosis (max. 60), mean ± SD | 56.5 | 5.0 | 107 | 55.6 | 4.6 | 24 | 56.7 | 5.2 | 83 | 0.35 |
| mRS at initial diagnosis, mean ± SD | 1.7 | 1.0 | 165 | 2.0 | 1.1 | 42 | 1.6 | 0.9 | 123 | 0.04 |
| Time between manifestation and diagnosis (months), mean ± SD | 37.1 | 42.6 | 184 | 34.7 | 42.7 | 47 | 38.0 | 42.8 | 137 | 0.65 |
| Disease duration before treatment with CYP, RTX, and/or BTZ (months), mean ± SD | 39.7 | 48.9 | 48 | |||||||
| Follow-up time (years), mean ± SD | 6.1 | 5.8 | 186 | 7.5 | 6.1 | 48 | 5.6 | 5.7 | 138 | 0.04 |
| Age at the end of follow up, mean ± SD | 63.4 | 13.4 | 200 | 63.0 | 12.4 | 48 | 63.5 | 13.7 | 152 | 0.81 |
| INCAT-ODSS at the end of follow up, mean ± SD | 3.1 | 2.4 | 194 | 4.8 | 2.9 | 48 | 2.5 | 1.8 | 146 | <0.001 |
BTZ, bortezomib; CYP, cyclophosphamide; INCAT-ODSS, inflammatory neuropathy cause and treatment overall disability score; MRC, Medical Research Council; mRS, modified Rankin scale; RTX, rituximab; SD, standard deviation.